7 completed, 2 terminated, 1 unknown. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 2, Unknown 1 |
Follow Pyelitis: new trials by email Literature Review of Pyelitis trials Research Report on Pyelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone)) - Urinary Tract Infections, Pyelonephritis | Phase 2 | Unknown | NeuroRx, Inc. | 13 | 2024-03-31 | 2023-11-13 |
| MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) Ceftolozane/Tazobactam, Meropenem - Complicated Urinary Tract Infection, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 134 | 2018-04-26 | 2023-05-06 |
| Effect of Acetylcysteine in Pediatric Acute Pyelonephritis. Acetylcysteine, placebo acetylcysteine - Pyelonephritis | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 70 | 2014-01-01 | 2016-04-20 |
| Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Finafloxacin 800 mg i.v. once daily, Finafloxacin placebo i.v. once daily, Finafloxacin 800 mg tablets once daily - Urinary Tract Infections, Acute Pyelonephritis | Phase 2 | Completed | MerLion Pharmaceuticals GmbH | 225 | 2012-12-01 | 2017-06-20 |
| Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg - Urinary Tract Infections, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 302 | 2012-05-16 | 2019-05-24 |
| Prospective Study in the Emergency care management arm N°1 vs arm N°2, Care management - Pyelonephritis | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 23 | 2012-05-01 | 2013-10-08 |
| GSK2251052 in Complicated Urinary Tract Infection GSK2251052, imipenem-cilastatin, Placebo - Infections, Urinary Tract | Phase 2 | Terminated | GlaxoSmithKline | 20 | 2011-06-28 | 2017-09-08 |
| Preventing Urinary Tract Infection Post-Surgery Cranberry powder capsules, Placebo powder capsules - Urinary Tract Infection | Phase 2 | Completed | Betsy Foxman | 200 | 2011-06-01 | 2015-06-10 |
| A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) levofloxacin, plazomicin, placebo - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Achaogen, Inc. | 145 | 2010-07-13 | 2018-08-22 |
| Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections CXA-101, Ceftazidime - Complicated Urinary Tract Infection | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 129 | 2009-06-30 | 2018-10-18 |
Pyelonephritis (10) · Urinary Tract Infections (6) · Cystitis (1) · Infections (1) · Urologic Diseases (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Kidney Diseases (10) · Male Urogenital Diseases (10) · Nephritis (10) · Nephritis, Interstitial (10) · Urogenital Diseases (10) · Urologic Diseases (9) · Infections (6) · Urinary Bladder Diseases (1)
Cilastatin, Imipenem Drug Combination (2) · Ciprofloxacin (2) · 3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (1) · Acetylcysteine (1) · Ceftazidime (1) · Cilastatin (1) · Cycloserine (1) · Imipenem (1) · Levofloxacin (1) · Lurasidone Hydrochloride (1) · Meropenem (1) · Sodium Chloride (1) · ceftolozane (1) · ceftolozane, tazobactam drug combination (1) · finafloxacin (1)
Merck Sharp & Dohme LLC (2) · Achaogen, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Betsy Foxman (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · GlaxoSmithKline (1) · MerLion Pharmaceuticals GmbH (1) · NeuroRx, Inc. (1) · Shahid Beheshti University of Medical Sciences (1)
United States (4) · France (2) · Germany (2) · Greece (2) · Poland (2) · Russia (2) · Canada (1) · Hungary (1) · Iran (1) · Mexico (1) · Romania (1) · South Africa (1) · Spain (1) · Turkey (Türkiye) (1) · Ukraine (1)
Ahmad Haidar, MD (1) · Betsy Foxman, PhD (1) · David Elkharrat, MD (1) · Florian Wagenlehner, MD (1) · Florian Wagenlehner, Prof. (1) · Michal Nowicki, Prof. (1) · Ryszard Gellert, MD (1)
PMID 25348524, PMID 25882919, PMID 28575389, PMID 29339393, PMID 29339394, PMID 29339395, PMID 31540834, PMID 36689671, PMID 37068952, PMID 37947276
2016 (1), R21DK085290 (1)